For some rare, life threatening conditions or those of major public interest, the early access to investigational drugs prior to regulatory approval is vital.
Representation of companies in EU & US.
We can help you navigate the complex environment of Early Access Programmes (EAP) in the EU and the US, we will work cross-functionally with your functional teams to ensure the correct timing of the EAP and strategically plan to avoid any possible hurdles. We have considerable experience in the arena of EAPs and can design and implement the programmes on your behalf in the EU and the US.
